Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
In development
Reference number: GID-TA11021
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2026.